Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Oct 10, 2006

Sigma-Aldrich Nabs Advanced Separation Technologies

  • Sigma-Aldrich acquired Advanced Separation Technologies (Astec), in a move that it believes will enhance its research specialties business unit’s chiral chromatography capabilities and product line, enabling the company to better support the analysis and purification of chiral compounds.

    “In addition to a wide range of proprietary chiral chromatography products, the acquisition of Astec brings the specialized knowledge of chiral separations embodied in its people,” comments Russel Gant, vp for Sigma-Aldrich’s chromatography manufacturing site.

    With annual revenues of roughly $2 million, the late-year acquisition will not have a material impact on the company’s sales but is expected to help the company meet its growth goals over the next several years. The transaction will be neutral to earnings in 2006, with no initial charges.



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »